Human pallial MGE-type GABAergic interneuron cell therapy for chronic focal epilepsy

Area of Science:

• Neuroscience
• Stem Cell Therapy
• Epilepsy Research

Background:

• Mesial temporal lobe epilepsy (MTLE) is the most prevalent form of focal epilepsy.
• A significant portion of MTLE patients (one-third) exhibit drug-refractory seizures, necessitating invasive treatments like epilepsy surgery.
• Current therapeutic options for drug-resistant MTLE are limited and often suboptimal.

Purpose of the Study:

• To develop and characterize a novel cell therapy for drug-resistant MTLE.
• To evaluate the efficacy and safety of human embryonic stem cell-derived GABAergic interneurons as a treatment for MTLE.
• To investigate the disease-modifying potential of this cell therapy in a preclinical model.

Main Methods:

• Development of a cell therapy using cryopreserved, post-mitotic medial ganglionic eminence (MGE) pallial-type GABAergic interneurons derived from human embryonic stem cells.
• Intrahippocampal delivery of a single dose of these interneurons into a mouse model of chronic MTLE.
• Assessment of seizure suppression, interneuron integration, long-term persistence, and reduction of dentate granule cell dispersion.

Main Results:

• Single-dose intrahippocampal administration led to consistent mesiotemporal seizure suppression, with a majority of animals becoming seizure-free and exhibiting increased survival.
• Grafted interneurons demonstrated local dispersion, functional integration, and long-term persistence within the hippocampus.
• The therapy significantly reduced dentate granule cell dispersion, a key pathological hallmark of MTLE, in a dose-dependent manner with a broad therapeutic range; no adverse effects were observed.

Conclusions:

• Human embryonic stem cell-derived MGE interneurons represent a viable and effective cell therapy for drug-resistant MTLE.
• The observed seizure suppression and reduction in pathological hallmarks suggest disease-modifying capabilities.
• These preclinical findings provide strong support for the ongoing phase 1/2 clinical trial evaluating this cell therapy in patients with drug-resistant MTLE.